Ningbo MedicalSystem Biotechnology Co Ltd (300439) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ningbo MedicalSystem Biotechnology Co Ltd (300439) has a cash flow conversion efficiency ratio of 0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥48.96 Million ≈ $7.16 Million USD) by net assets (CN¥2.95 Billion ≈ $431.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ningbo MedicalSystem Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ningbo MedicalSystem Biotechnology Co Lt total liabilities for a breakdown of total debt and financial obligations.
Ningbo MedicalSystem Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ningbo MedicalSystem Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northfield Bancorp Inc
NASDAQ:NFBK
|
0.020x |
|
Korea Line
KO:005880
|
0.039x |
|
Zhejiang Runyang New Material Technology Co. Ltd.
SHE:300920
|
-0.003x |
|
Guan Chong Bhd
KLSE:5102
|
0.169x |
|
Qingdao Liqun Department Store Group Co Ltd
SHG:601366
|
0.155x |
|
AMERISAFE Inc
NASDAQ:AMSF
|
0.009x |
|
Qinghai Huzhu Barley Wine Co Ltd
SHE:002646
|
0.000x |
|
Epigral Ltd.
NSE:EPIGRAL
|
0.029x |
Annual Cash Flow Conversion Efficiency for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 300439 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.93 Billion ≈ $429.26 Million |
CN¥397.81 Million ≈ $58.21 Million |
0.136x | -42.06% |
| 2023-12-31 | CN¥2.71 Billion ≈ $396.07 Million |
CN¥633.53 Million ≈ $92.71 Million |
0.234x | +4.43% |
| 2022-12-31 | CN¥2.52 Billion ≈ $368.67 Million |
CN¥564.67 Million ≈ $82.63 Million |
0.224x | +3.95% |
| 2021-12-31 | CN¥2.39 Billion ≈ $349.84 Million |
CN¥515.48 Million ≈ $75.43 Million |
0.216x | -60.12% |
| 2020-12-31 | CN¥1.69 Billion ≈ $246.86 Million |
CN¥912.07 Million ≈ $133.47 Million |
0.541x | +24.86% |
| 2019-12-31 | CN¥1.39 Billion ≈ $203.16 Million |
CN¥601.17 Million ≈ $87.97 Million |
0.433x | +134.69% |
| 2018-12-31 | CN¥2.27 Billion ≈ $332.15 Million |
CN¥418.80 Million ≈ $61.28 Million |
0.185x | +428.61% |
| 2017-12-31 | CN¥2.29 Billion ≈ $334.63 Million |
CN¥-128.40 Million ≈ $-18.79 Million |
-0.056x | -4283.55% |
| 2016-12-31 | CN¥1.83 Billion ≈ $267.53 Million |
CN¥2.45 Million ≈ $359.05K |
0.001x | -99.03% |
| 2015-12-31 | CN¥1.29 Billion ≈ $188.39 Million |
CN¥177.55 Million ≈ $25.98 Million |
0.138x | -50.86% |
| 2014-12-31 | CN¥415.13 Million ≈ $60.75 Million |
CN¥116.51 Million ≈ $17.05 Million |
0.281x | -13.52% |
| 2013-12-31 | CN¥308.32 Million ≈ $45.12 Million |
CN¥100.06 Million ≈ $14.64 Million |
0.325x | +40.55% |
| 2012-12-31 | CN¥202.58 Million ≈ $29.64 Million |
CN¥46.78 Million ≈ $6.85 Million |
0.231x | -48.63% |
| 2011-12-31 | CN¥110.84 Million ≈ $16.22 Million |
CN¥49.82 Million ≈ $7.29 Million |
0.450x | -- |
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more